On Tuesday, Baxter International Inc (NYSE:BAX) agreed to sell its Kidney Care segment, Vantive, for $3.8 billion to The Carlyle Group Inc (NASDAQ:CG) Baxter will receive approximately $3.5 billion in cash, with net after-tax proceeds currently estimated at approximately $3 billion. Baxter announced its intention to create a standalone kidney care company in January 2023 as part of its broader strategic realignment designed to enhance future performance and create value for all stakeholders. In March 2024, Baxter announced that it was in discussions to explore a potential sale ...